EUVIMEDEUVIMED entdecken
Crossref

A Universal Single‐Activated‐Dual‐Release Vehicle: Enabling Synergistic Antitumor Therapy

Jinliang Han, Mingwang Yang, Kang Li, Wenkai Liu, Jiangli Fan iD, Xiaojun Peng

Small · 2025

DOI: 10.1002/smll.202410925 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2025. Verfasst von Jinliang Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Fine Chemicals, Frontier Science Center for Smart Materials, Dalian University of Technology, Dalian, 116023, China. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Liaoning Binhai Laboratory, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activatable combined therapeutic strategy exhibits significant potential for the management of malignant tumors. Ensuring the timely and spatially effective release of different therapeutic agents is a great challenge for maximizing the efficacy of combination therapy. Herein, based on the 1,4‐and 1,6‐elimination behaviors, the study proposes a novel universal single‐activated‐dual‐release platform that can be triggered by various stimulants of interest. As a proof‐of‐concept, the study develops an example of a synergistic therapy called CyI‐Cbl‐NTR , which can be selectively activated by nitroreductase (NTR) to release the photosensitizer ( CyI‐OH ) and DNA alkylating agent chlorambucil (Cbl), thereby enabling a combination of chemo‐ and photodynamic therapy. Both in vitro and in vivo experiments fully demonstrate the remarkable combined therapeutic effect of Cyl‐Cbl‐NTR and the feasibility of this strategy. This work provides a promising platform for the future development of activatable synergistic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsAnimalsHumansChlorambucilPhotosensitizing AgentsPhotochemotherapyCell Line, TumorMiceNitroreductasesMice, Inbred BALB CDrug Synergism

Stichwörter der Autor:innen

activatabledual‐releasesynergistic therapytumorvarious stimulants

Substanzen

ChlorambucilPhotosensitizing AgentsAntineoplastic AgentsNitroreductases

Autor:innen und Institutionen

  • State Key Laboratory of Fine Chemicals, Frontier Science Center for Smart Materials, Dalian University of Technology, Dalian, 116023, China.
  • Liaoning Binhai Laboratory, Dalian, 116023, China.

ORCID-Profile: Jiangli Fan

Förderung

  • National Natural Science Foundation of China
  • Liaoning Binhai Laboratory
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Han, J., Yang, M., Li, K., Liu, W., Fan, J., & Peng, X. (2025). A Universal Single‐Activated‐Dual‐Release Vehicle: Enabling Synergistic Antitumor Therapy. Small. https://doi.org/10.1002/smll.202410925

Vancouver

Han J, Yang M, Li K, Liu W, Fan J, Peng X. A Universal Single‐Activated‐Dual‐Release Vehicle: Enabling Synergistic Antitumor Therapy. Small. 2025. doi:10.1002/smll.202410925

BibTeX
@article{Han2025,
  author = {Han, Jinliang and Yang, Mingwang and Li, Kang and Liu, Wenkai and Fan, Jiangli and Peng, Xiaojun},
  title = {A Universal Single‐Activated‐Dual‐Release Vehicle: Enabling Synergistic Antitumor Therapy},
  journal = {Small},
  year = {2025},
  doi = {10.1002/smll.202410925}
}
Kostenlos starten →